Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

AstraZeneca and GSK have announced separate agreements with China's Sino Biopharm, reinforcing a growing trend of cross-border pharmaceutical partnerships. AstraZeneca licensed an investigational respiratory medicine, while GSK expanded its commercial collaboration in China. The announcements come as regulators increasingly examine
ConcertAI has expanded its CancerLinQ platform beyond quality reporting into an AI-powered clinical decision support system that integrates trial matching, structured data extraction, and real-time oncology insights. The announcement highlights a broader industry shift: as AI becomes part of clinical
The European Medicines Agency (EMA) has started a phased review of daraxonrasib, an investigational therapy for metastatic pancreatic cancer. However, the biggest story is not the medicine itself. Instead, the review marks one of the first real-world applications of a
Compass Pathways has reported new six-month Phase III data showing that its psilocybin-based therapy, COMP360, continued to provide durable clinical benefits for patients with treatment-resistant depression. While the efficacy results attracted attention, the announcement also moves the therapy closer to
Penn Medicine has integrated K Health’s AI-powered patient intake agents into its virtual primary care service, marking another step toward embedding AI agents into regulated clinical workflows. Rather than replacing clinicians, the system gathers patient information before appointments and delivers
New pharmaceutical manufacturing investments are beginning to reshape the U.S. biotech landscape beyond traditional hubs like Boston and Cambridge. According to a report by Alexandra Pecci published on July 6, Lancaster County, Oklahoma City and Las Vegas are attracting major
The Centers for Medicare & Medicaid Services (CMS) has released its proposed 2027 Hospital Outpatient Prospective Payment System rule, introducing a 2.4% outpatient payment increase while proposing significant reductions in the 340B Drug Pricing Program reimbursement and expanding site-neutral payment
Abivax has reported new Phase III maintenance data showing that obefazimod maintained a favorable benefit-risk profile in adults with moderate to severe ulcerative colitis, despite safety concerns raised only weeks earlier. The updated findings strengthen the company's planned New Drug
AstraZeneca has entered a $1.7 billion kidney disease drug discovery partnership with China-based CSPC Pharmaceutical Group, expanding their ongoing collaboration into renal therapeutics using siRNA-based drug discovery and AI-driven molecular design systems. The agreement, announced on July 3, 2026, aims
The European Medicines Agency (EMA) has launched a major initiative to address long-standing gaps in women’s health representation within clinical trials and regulatory evidence frameworks. Announced on 2 July 2026, the initiative focuses on improving sex-based data integration in drug